Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215085 | 1.00 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1430069 | 1.00 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL956167 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1351322 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL956164 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1864395 | 0.89 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1864392 | 0.89 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL24298421 | 0.88 | CTSK (0.64) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL3814592 | 0.88 | CTSK (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL952036 | 0.88 | CTSK (0.64) | CTSSCTSKAAK1IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3491005-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-109563136-A | Cyclic peptide as C5a receptor antagonist | 辉瑞公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018020358-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | C3AR1, C5AR1, C5AR2 | CTSS 1540/4885CTSK 1530/4885AAK1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.